Exabis Library
Welcome to the e-CCO Library!
P431: Early mucosal healing at week 10 with ozanimod predicts clinical outcomes at week 52: Post hoc analysis of the phase 3 True North clinical trial
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P431: Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodology
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P431: Teduglutide use and nutritional outcomes in short bowel syndrome with intestinal failure: a real-world claims database analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P431: Transabdominal ultrasonography to assess intestinal wall thickness and vascularity appears to predict therapeutic effects of steroid treatment in moderate-to-severe ulcerative colitis patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P431: Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P432 Effects and safety of a colon-long absorbing budesonide product in patients with mild to moderate ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P432: Barriers to prescribing anti-TNF therapy in inflammatory bowel disease (IBD) across newly industrialised emerging market countries: an analysis of the ‘EXPLORE’ study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P432: Does medical acceleration improve long-term outcomes in ulcerative colitis patients who are in clinical remission but have endoscopic mucosal inflammation?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P432: MyChart application in addressing Inflammatory Bowel Disease patients’ concerns and impact on service utilisation
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P432: Patient perspectives on biosimilars: a European Federation of Crohn’s and Colitis Associations survey
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P432: Patient satisfaction and patient costs associated with telephone clinic appointments in Inflammatory Bowel Disease (IBD) following the pandemic
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P432: Relationship between haemoglobin status and utility in patients with iron deficiency anaemia in inflammatory bowel disease: A post-hoc analysis of a phase 3 clinical trial
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P432: Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's disease – a multicentre cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P433: Aetiologies of iron deficiency-related anaemia in German patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P433: Canadian patient and caregiver perspectives on subsequent entry biologics / biosimilars for inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P433: Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P433: Faecal calprotectin is correlated to endoscopic disease activity at Week 16 in IBD patients on vedolizumab therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P433: Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P433: Postsurgical recurrence in Crohn's disease. Multicenter study in the region of Murcia, Spain of GEMEII group
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM